New targeted drug versus standard chemotherapy for endometrial cancer

This study compares a new targeted drug called Trastuzumab Deruxtecan (Enhertu) with standard chemotherapy for endometrial cancer patients whose tumors have high levels of a protein called HER2. The medication works by targeting cancer cells that express this protein and delivering a powerful cancer-fighting agent directly to them. Researchers want to see if this approach helps people stay cancer-free longer than traditional chemotherapy alone.

Standard chemotherapy for endometrial cancer has helped many patients, but doctors want to find better options—especially for patients whose cancers have the HER2 protein. This targeted approach may be more effective and potentially have fewer side effects because it focuses on cancer cells rather than healthy cells throughout the body.